ZIC5

Across TCGA pan-cancer cohorts, ZIC5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZIC5 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZIC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZIC5 expression acts as an unfavorable survival marker.

HNSC, LUSC, and BRCA are the cancer types where ZIC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.074	0.770	<.001	48	view →
LUSC	OS	Median	All	0.147	0.776	.001	36	view →
BRCA	OS	Median	All	0.256	0.924	<.001	24	view →
LUAD	OS	Median	II,III,IV	0.079	0.677	<.001	15	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZIC5–HNSC (OS)

Open the HNSC breakdown →